Cytiva, a global life sciences company, and Pear Bio, a pioneer in personalized cancer medicine, are collaborating to advance cancer research and personalized treatment. Pear Bio is using Cytiva’s Via Extractor technology to create dissociated tumor cell suspensions with high viability and yield, revolutionizing tumor cell analysis.
 
Pear Bio processes tumor cells and matched patient immune cells, culturing them ex vivo in 3D environments to test the efficacy of FDA-approved therapies specific to various cancer indications using Cytiva’s Via Extractor tissue disaggregator technology. Over five days, a confocal scanning microscope performs 3D imaging of the microtumors, and Pear Bio’s Computer Vision Pipeline analyzes the data to generate dozens of phenotypic biomarkers that reveal the drug’s impact on the microtumors. The quality and viability of these tumor cells in their single-cell suspension are critical to Pear Bio’s downstream workflow, ensuring precise and reliable results.
  
Tim Bervoets, President, Discovery & Medical, Cytiva, said, “This advancement is a significant step forward in the fight against cancer. By leveraging our Via Extractor technology, Pear Bio reaches the cell viability and integrity levels that are essential for their advanced cancer treatment research. Together, we aim to enhance the effectiveness of cancer therapies and improve patient outcomes.”
 
John Curran, Chief Operating Officer & Laboratory Director, Pear Bio, said, “We are thrilled with the performance of Cytiva’s Via Extractor in our workflows. The high cell viability and integrity it provides are critical for our novel cancer medicine analysis, enabling us to achieve more reliable and efficient results.”
 
Pear Bio has integrated the Via Extractor into their workflows across both UK and US sites, ensuring consistently high cell viability and continuity in testing. Pear Bio already operates Via Extractors in their labs at both locations.